Roman Galetto

USPTO Granted Patents = 25 (Patent Applications = 21)

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 14 (Patent Applications = 26)

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 94(Granted Patents)

Company Filing History:

Years Active: 2018-2024

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12152081 - Chimeric antigen receptors targeting CD70 (2024-11-26),

2. 11919961 - CD123 specific chimeric antigen receptors for cancer immunotherapy (2024-03-05),

3. 11912776 - Chimeric antigen receptors targeting B-cell maturation antigen (2024-02-27),

4. 11891614 - Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy (2024-02-06),

5. 11603539 - Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy (2023-03-14),

6. 11498971 - BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy (2022-11-15),

7. 11414674 - Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells (2022-08-16),

8. 11396551 - Chimeric antigen receptors targeting CD70 (2022-07-26),

9. 11312782 - Chimeric antigen receptors targeting B-cell maturation antigen (2022-04-26),

10. 11311575 - Methods for engineering highly active T cell for immunotherapy (2022-04-26),

11. 11304975 - Methods for engineering allogeneic and highly active t cell for immunotherapy (2022-04-19),

12. 11274316 - Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells (2022-03-15),

13. 11077144 - CD19 specific chimeric antigen receptor and uses thereof (2021-08-03),

14. 11007224 - CD19 specific chimeric antigen receptor and uses thereof (2021-05-18),

15. 10988541 - CD123 specific chimeric antigen receptors for cancer immunotherapy (2021-04-27),

Title: Roman Galetto: Innovator in Cancer Immunotherapy

Introduction

Roman Galetto, based in Paris, France, is a prominent inventor in the field of cancer immunotherapy. With an impressive portfolio of 25 patents, he has made significant contributions to innovations that enhance the effectiveness of immune cell therapies. His work has profound implications for the treatment of various malignancies.

Latest Patents

Among Galetto's most recent patents are:

1. **Chimeric Antigen Receptors Targeting CD70**: This innovative disclosure elaborates on CARs that specifically bind to CD70. The patent includes engineered immune cells that incorporate these CARs, along with CAR-encoding nucleic acids. Furthermore, it presents therapeutic methods utilizing these CARs for treating conditions associated with malignant cells expressing CD70, notably in cancer.

2. **CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy**: This patent focuses on recombinant chimeric proteins designed to redirect immune cell specificity toward specific membrane antigens. The extracellular ligand binding is derived from a CD123 monoclonal antibody, targeting CD123 positive cells. The engineered immune cells endowed with these CARs are particularly effective for treating lymphomas and leukemia.

Career Highlights

Roman Galetto has had an impactful career, having worked with industry giants such as Cellectis and Pfizer Corporation. His expertise and innovative spirit have positioned him as a leader in the research and development of cutting-edge therapies in cancer treatment.

Collaborations

Throughout his career, Galetto has collaborated with notable professionals, including Julianne Smith and Andrew M Scharenberg. These collaborations have further advanced the realms of immunotherapy and the development of effective cancer treatments.

Conclusion

Roman Galetto stands out as an influential inventor with significant advancements in cancer immunotherapy through his innovative patents. His dedication to harnessing the power of engineered immune cells has the potential to transform the landscape of cancer treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.